|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.00 USD | -5.51% |
|
-2.15% | -21.79% |
| 11:36am | IRenix Medical, Inc., Tarsus Pharmaceuticals, Inc. - M&A Call | |
| 09/07 | Tarsus Pharmaceuticals Buys iRenix Medical | MT |
| Market Cap | 291.4Cr 254.92Cr 235.08Cr 217.5Cr 412.83Cr 28TCr 419.73Cr 2.82TCr 1.1TCr 14TCr 1.09TCr 1.07TCr 47TCr | P/E 2026 * |
-108x | P/E 2027 * | 22x |
|---|---|---|---|---|---|
| Enterprise Value | 291.4Cr 254.92Cr 235.08Cr 217.5Cr 412.83Cr 28TCr 419.73Cr 2.82TCr 1.1TCr 14TCr 1.09TCr 1.07TCr 47TCr | EV / Sales 2026 * |
4.18x | EV / Sales 2027 * | 3.22x |
| Free-Float |
96.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Tarsus Pharmaceuticals, Inc.
| 1 day | -5.55% | ||
| 1 week | -2.15% | ||
| Current month | +1.74% | ||
| 1 month | +4.04% | ||
| 3 months | -11.58% | ||
| 6 months | -16.70% | ||
| Current year | -21.79% |
| 1 week | 61.71 |  | 72.5 |
| 1 month | 56.51 | | 72.5 |
| Current year | 56 | | 83.92 |
| 1 year | 38.51 | | 85.25 |
| 3 years | 12.57 | | 85.25 |
| 5 years | 10.8 | | 85.25 |
| 10 years | 10.8 | | 85.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 48 | 01/09/2018 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 64 | 24/04/2023 |
| Chief Tech/Sci/R&D Officer | 47 | 04/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CHM | Chairman | 48 | 02/12/2022 |
| Director/Board Member | 71 | 01/12/2019 | |
Bill Link
BRD | Director/Board Member | 80 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/06 | Free | Director | 6,254 | 0.0145% | ||
| 25/06 | Free | Director | 7,463 | 0.0173% | ||
| 25/06 | Free | Director | 6,254 | 0.0145% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.51% | -2.15% | +55.09% | +259.34% | 291.4Cr | |
| +0.44% | +1.94% | +20.70% | -5.18% | 6.74TCr | |
| +0.52% | -5.52% | +46.80% | +218.71% | 5.4TCr | |
| -2.79% | +32.50% | +32.50% | +32.50% | 4.18TCr | |
| +0.99% | +6.05% | -48.96% | -52.97% | 4.11TCr | |
| -0.39% | -7.41% | +50.43% | -28.94% | 2.96TCr | |
| +2.82% | -5.28% | +130.41% | -38.62% | 2.93TCr | |
| +0.72% | +1.20% | +72.09% | +91.08% | 2.34TCr | |
| +0.17% | +8.48% | +4.86% | +185.45% | 1.91TCr | |
| +1.14% | -0.17% | +68.83% | +134.48% | 1.68TCr | |
| Average | -0.20% | +2.29% | +43.27% | +79.59% | 3.25TCr | |
| Weighted average by Cap. | +0.24% | +1.14% | +35.87% | +53.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 70Cr 61Cr 56Cr 52Cr 99Cr 6.65TCr 100.3Cr 672.75Cr 263.72Cr 3.26TCr 261.42Cr 255.77Cr 11TCr | 90Cr 79Cr 73Cr 68Cr 128.15Cr 8.63TCr 130.29Cr 873.85Cr 342.55Cr 4.24TCr 339.57Cr 332.22Cr 15TCr |
| Net income | -2.85Cr -2.49Cr -2.3Cr -2.13Cr -4.03Cr -271.82Cr -4.1Cr -28Cr -11Cr -133.48Cr -11Cr -10Cr -462.36Cr | 16Cr 14Cr 13Cr 12Cr 22Cr 1.51TCr 23Cr 152.59Cr 60Cr 740.32Cr 59Cr 58Cr 2.56TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/26/09 | $63.83 | -5.75% | 13,53,473 |
| 08/26/08 | $67.73 | -4.00% | 13,30,643 |
| 07/26/07 | $70.55 | +5.22% | 16,85,124 |
| 06/26/06 | $67.05 | +2.46% | 14,58,724 |
| 02/26/02 | $65.44 | +7.47% | 17,85,690 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TARS Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
